Manganese produce a parkinsonism-like illness characterized by movement abnormalities. This condition is not responsive to typical therapies used in the treatment of PD, suggesting an alternative pathway than the typical dopaminergic loss within the substantia nigra. Manganese may accumulate in the basal ganglia, leading to the abnormal movements. A mutation of the SLC30A10 gene, a manganese efflux transporter necessary for decreasing intracellular Mn, has been linked with the development of this Parkinsonism-like disease. The Lewy bodies typical to PD are not seen in Mn-induced parkinsonism. Animal experiments have given the opportunity to examine the consequences of manganese overexposure under controlled conditions.
Manganese(III) fluoride octahedral, and trivalent in all of these materials. Manganese(III) fluoride fluorinates organic compounds including aromatic hydrocarbons, cyclobutenes, and fullerenes. On heating, MnF decomposes to manganese(II) fluoride. Manganese(III) fluoride Manganese(III) fluoride (also known as Manganese trifluoride) is the inorganic compound with the formula MnF. This red/purplish solid is useful for converting hydrocarbons into fluorocarbons, i.e., it is a fluorination agent. It forms a hydrate and many derivatives. MnF can be prepared by treating a solution of MnF in hydrogen fluoride with fluorine: It can also be prepared by the reaction of elemental fluorine with a manganese(II) halide at ~250 °C. Like